Join
Live feed
·
PRReleasevia Quantisnow
Nasus Pharma Ltd. logo

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

ByQuantisnow·Wall Street's wire, on your screen.
NSRX· Nasus Pharma Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NSRX (Nasus Pharma Ltd.) and more on Quantisnow.